Lotus Pharmaceutical Co Ltd (TW:1795) — Market Cap & Net Worth
Market Cap & Net Worth: Lotus Pharmaceutical Co Ltd (1795)
Lotus Pharmaceutical Co Ltd (TW:1795) has a market capitalization of $1.50 Billion (NT$47.50 Billion) as of September 16, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #7242 globally and #217 in its home market, demonstrating a -1.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lotus Pharmaceutical Co Ltd's stock price NT$178.50 by its total outstanding shares 266090757 (266.09 Million). Also see 1795 asset base for a full breakdown of the balance sheet.
Lotus Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Lotus Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $572.33 Million to $1.50 Billion (8.73% CAGR). Also see 1795 cash flow conversion for how efficiently the company converts equity into cash flow.
Lotus Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lotus Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 1795 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.12x
Lotus Pharmaceutical Co Ltd's market cap is 0.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.50x
Lotus Pharmaceutical Co Ltd's market cap is 0.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $493.28 Million | $5.90 Billion | -$134.04 Million | 0.08x | N/A |
| 2017 | $419.99 Million | $6.42 Billion | $7.68 Million | 0.07x | 54.65x |
| 2018 | $610.22 Million | $6.43 Billion | $99.48 Million | 0.09x | 6.13x |
| 2019 | $947.03 Million | $9.17 Billion | $662.81 Million | 0.10x | 1.43x |
| 2020 | $658.80 Million | $10.73 Billion | $1.03 Billion | 0.06x | 0.64x |
| 2021 | $805.55 Million | $12.65 Billion | $1.40 Billion | 0.06x | 0.57x |
| 2022 | $2.06 Billion | $14.63 Billion | $3.02 Billion | 0.14x | 0.68x |
| 2023 | $2.28 Billion | $16.96 Billion | $4.11 Billion | 0.13x | 0.56x |
| 2024 | $2.26 Billion | $18.58 Billion | $5.07 Billion | 0.12x | 0.45x |
| 2025 | $2.37 Billion | $20.51 Billion | $4.72 Billion | 0.12x | 0.50x |
Competitor Companies of 1795 by Market Capitalization
Companies near Lotus Pharmaceutical Co Ltd in the global market cap rankings as of September 16, 2026. Review Lotus Pharmaceutical Co Ltd (1795) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Lotus Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Lotus Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Lotus Pharmaceutical Co Ltd's market cap moved from $572.33 Million to $ 1.50 Billion, with a yearly change of 8.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$1.50 Billion | -36.93% |
| 2025 | NT$2.37 Billion | +5.01% |
| 2024 | NT$2.26 Billion | -0.92% |
| 2023 | NT$2.28 Billion | +10.57% |
| 2022 | NT$2.06 Billion | +156.01% |
| 2021 | NT$805.55 Million | +22.28% |
| 2020 | NT$658.80 Million | -30.43% |
| 2019 | NT$947.03 Million | +55.20% |
| 2018 | NT$610.22 Million | +45.29% |
| 2017 | NT$419.99 Million | -14.86% |
| 2016 | NT$493.28 Million | -13.81% |
| 2015 | NT$572.33 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Lotus Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.50 Billion USD |
| MoneyControl | $1.50 Billion USD |
| MarketWatch | $1.50 Billion USD |
| marketcap.company | $1.50 Billion USD |
| Reuters | $1.50 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lotus Pharmaceutical Co Ltd
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines;… Read more